Mostrar mensagens com a etiqueta canakinumab. Mostrar todas as mensagens
Mostrar mensagens com a etiqueta canakinumab. Mostrar todas as mensagens

domingo, 28 de abril de 2019

A inflamação e o seu papel noutras doenças?

... algumas crónicas:

https://harvardmagazine.com/2019/05/inflammation-disease-diet

Citando:
"We knew that regular exercise does reduce inflammation over the long term, but we also knew that acute exercise transiently increases inflammatory biomarkers during and immediately after exertion.” About a third of the benefit of regular exercise, they found, is attributable to reduced inflammation.

The anti-inflammatory effect of exercise was much greater than most people had expected. That raised another question: whether inflammation might also play a dominant role in other lifestyle illnesses that have been linked to cardiovascular disease, such as diabetes and dementia."

(...)

"canakinumaban orphan drug that blocks a specific pro-inflammatory pathway called IL-1beta. But some researchers suggest that the inflammatory process—a normal and necessary part of the natural immune response—has itself has been misunderstood. Scientists know that the process can be turned on and off, but have only recently understood that this doesn’t mean normal physiology will resume once the inflammation caused by infection, injury, or irritant has been shut down. Instead, the restoration of health is an active phase of the inflammatory process itself, facilitated by a little-known class of molecules called pro-resolving mediators—the protectins, resolvins, maresins, and lipoxins—brimming with marvelous, untapped, regenerative capacities.(...)"


segunda-feira, 28 de agosto de 2017

Ai o substituto das estatinas?

http://www.telegraph.co.uk/science/2017/08/27/new-wonder-drug-hailed-biggest-breakthrough-fight-against-heart/

Citando:
"Cholesterol-busting statins are given to millions of adults deemed to be at risk of heart disease.

But half of heart attacks occur in people who do not have high cholesterol at all.

Now scientists have found that reducing inflammation in the body can protect against a host of conditions - with a “really dramatic effect” on cancer deaths.

The drug canakinumab, given by injection every three months - cut repeat heart attacks by one quarter. Statins cut the risk by around 15 per cent."

O preço:
"The new treatment - which works by blocking part of the immune system called interleukin-1 - currently costs around £40,000 annually to treat a patient with the drug, compared to just £20 for statins."